Navigation Links
CosmosID unveils new tool for faster, specific and accurate testing of probiotics products
Date:5/20/2013

Washington, D.C., May 20, 2013 CosmosID, a leading data mining solutions company for health and wellness, has reported as part of a collaboration results on analysis of labeling claims for the composition of probiotic products comparing speed, specificity, and accuracy.

The Food and Drug Administration (FDA) and CosmosID conducted side-by-side analysis of a number of commercially available probiotics, four of which have been reported at the American Society for Microbiology. The purpose of the tests was to compare the identity of species and strains present in the products to what was stated on their respective labels.

An Illumnia MiSeq sequencer was utilized to produce whole genome sequence files of the mixture of bacteria contained in the probiotic. Sequencing produced DNA fragments associated with each strain contained in the sample and was the basis for analyses to determine the amount and type of active ingredients contained in the probiotics. For the side-by-side testing, the FDA used conventional k-mer approach developed in house. CosmosID used its GENIUS product, NmerCE.

Overall, both the FDA's k-mer and CosmosID's NmerCE approaches were able to determine the active ingredients in each probiotic, as well as whether contaminants were present. The advantage of CosmosID's Genius product over the FDA's k-mer counting was both the speed at which the CosmosID's NmerCE was able to complete the analysis, and the ability to provide enhanced specificity in separating different species groups into specific strains.

The results were summarized in an abstract submitted by the FDA at the 133rd General Meeting of the American Society for Microbiology (ASM), which stated "In total, we developed a package of molecular approaches that stratifies genetic depth and regulatory need for appropriate strain identification for voluntary submissions but have widely useful applications from GMP surveillance for unexpected pathogens." Results will be presented May 19 at the ASM Denver meeting.

According to CosmosID's CTO and lead scientist, Dr. Thomas A. Cebula, and Dr. Nur A. Hasan, director, CosmosID Genomics R&D, "Utilization of our algorithms helps remove the computational bottleneck associated with metagenomic analyses, thus facilitating rapid detection, identification, and quantification of microbes in complex samples. As probiotic bacteria are becoming increasingly important in the context of human health, CosmosID GENIUS product will be extremely valuable for the industry in speed of use, quality control, quality assessment, and safety evaluations."

"CosmosID's Genius product will enable manufacturers of probiotics to quickly and accurately validate the labeling of their products for GMP surveillance for unexpected pathogens, or aid in developing and testing new probiotic products," stated CosmosID's chief executive officer, Doug Brenner. "Widespread use of strain-specific analysis of probiotics and their effects on microbial populations will level the playing field in the probiotics industry to assist in documenting efficacy and support labeling claims of companies that conduct rigorous testing against those that choose not to do so."


'/>"/>

Contact: Robin Buckley
robin@buckleykaldenbach.com
703-201-3524
Buckley & Kaldenbach, Inc.
Source:Eurekalert

Related medicine news :

1. IQware Solutions Unveils New Website, New Corporate Identity
2. CustomerCentric Selling® Unveils New Client Testimonial Videos to Showcase Significant Sales Success
3. DRE Medical Equipment Unveils FX-300+ Surgical Headlight and Light Source
4. 'EMT Exam Ace' Unveils Free Sample EMT Practice Quizzes
5. Taiho Pharmaceutical unveils data on 8 novel anticancer compounds
6. Naturel Collagen Canada Unveils C RUM, the Newest Addition to the Revolutionary Natural Collagen Skin Care Product Line
7. ShopPharmacyCounter.com Unveils PhenObestin 37.5 to Offset Obesity Effectively
8. Garden Media Unveils 2013-14 Garden Trends: ‘Finding Bliss in the Garden’- Part 3
9. Garden Media Group Unveils New Marketing and Public Relations Blog, GROW
10. Physicians Indemnity Risk Retention Group Unveils New Website
11. Marketing Xocolate International Corporation (MXI Corp) Unveils New Healthy Dark Chocolate Product: Xoçai™ Nuggets, Which Are Both Diabetic And Vegan Friendly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging ... Anti-aging Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, ...
(Date:12/5/2016)... ... 2016 , ... A newly released study has found that ... accuracy of placing precordial electrodes with little cognitive effort and a high degree ... studies have shown that single electrode misplacement is one of the single largest ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... in New York City, with long-time partners The Paul Foundation, on November 10, ...
(Date:12/4/2016)... ... 03, 2016 , ... While James Earl Jones is known for myriad roles ... show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a very ... in large part due to early detection. Like any other disease, treatments have a ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec 5, 2016 Research and Markets ... Market - Global Forecast to 2021" report to their offering. ... , , ... reach 17.27 billion by 2021, at a CAGR of 5.3% from 2016 ... growing number of obesity cases, increasing government spending on healthcare, and rising ...
(Date:12/5/2016)... PharmaBoardroom today releases its new 70 page Switzerland Healthcare & Life ... , , ... stakeholders crucial insight into Switzerland ; a country located ... of the world,s most important international health institutions as well as two ... number one ranking globally in terms of ease of doing business and ...
(Date:12/4/2016)... , Dec. 4, 2016 Blueprint ... in discovering and developing targeted kinase medicines for ... from its ongoing Phase 1 trial evaluating BLU-285, ... with advanced systemic mastocytosis (SM). Blueprint Medicines is ... of D816V mutant KIT. Approximately 90 to 95 ...
Breaking Medicine Technology: